PMID- 28019064
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 47
IP  - 4
DP  - 2017 Mar
TI  - Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 
      diabetes mellitus.
PG  - 266-280
LID - 10.1111/hepr.12856 [doi]
AB  - Liver-related diseases are the leading causes of death in patients with type 2 
      diabetes mellitus (T2DM) in Japan. Type 2 diabetes mellitus is closely associated 
      with non-alcoholic fatty liver disease (NAFLD), which is the most prevalent 
      chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), a severe 
      form of NAFLD, can lead to hepatocellular carcinoma and hepatic failure. 
      Non-alcoholic steatohepatitis can be called "diabetic hepatopathy". There are no 
      established pharmacotherapies for NAFLD/NASH patients with T2DM. Although 
      metformin is established as the first-line therapy for T2DM, given its relative 
      safety and beneficial effects on glycosylated hemoglobin, weight, and 
      cardiovascular mortality, this agent is not recommended as specific therapy for 
      NASH/NAFLD due to lack of clinical evidence. The effects of pioglitazone on NASH 
      histology with T2DM have been extensively proved, but several concerns exist, 
      such as body weight gain, fluid retention, cancer incidence, and bone fracture. 
      In recent years, novel antidiabetic medications have been approved for T2DM, such 
      as glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, 
      and sodium/glucose cotransporter 2 inhibitors. A key clinical question for 
      hepatologists is what kinds of antidiabetic medications are the most appropriate 
      for the treatment of NAFLD accompanied by T2DM, to prevent progression of hepatic 
      fibrosis resulting in HCC/liver-related mortality without increased risk of 
      cardiovascular events. This review focuses on novel antidiabetic agents and 
      future perspectives on the treatment of NAFLD/NASH with T2DM.
CI  - (c) 2017 The Japan Society of Hepatology.
FAU - Sumida, Yoshio
AU  - Sumida Y
AD  - Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi 
      Medical University, Nagakute, Japan.
FAU - Seko, Yuya
AU  - Seko Y
AD  - Department of Gastroenterology and Hepatology, Kyoto Prefectural University of 
      Medicine, Kyoto, Japan.
FAU - Yoneda, Masashi
AU  - Yoneda M
AD  - Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi 
      Medical University, Nagakute, Japan.
CN  - Japan Study Group of NAFLD (JSG-NAFLD)
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170213
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - dipeptidyl peptidase 4
OT  - glucagon-like peptide 1 receptor
OT  - sodium/glucose cotransporter 2
EDAT- 2016/12/27 06:00
MHDA- 2016/12/27 06:01
CRDT- 2016/12/27 06:00
PHST- 2016/12/01 00:00 [received]
PHST- 2016/12/22 00:00 [revised]
PHST- 2016/12/23 00:00 [accepted]
PHST- 2016/12/27 06:00 [pubmed]
PHST- 2016/12/27 06:01 [medline]
PHST- 2016/12/27 06:00 [entrez]
AID - 10.1111/hepr.12856 [doi]
PST - ppublish
SO  - Hepatol Res. 2017 Mar;47(4):266-280. doi: 10.1111/hepr.12856. Epub 2017 Feb 13.